Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

This large review pooled 113 studies (nearly 30,000 people) comparing different forms of blood phosphorylated tau for detecting Alzheimer's pathology. p-tau217 was clearly the best-performing marker, correctly identifying disease pathology about 88% of the time, outperforming other tau variants like p-tau181. The authors also flagged that most existing studies have methodological weaknesses that could inflate reported accuracy.

What this study adds

Evidence grade: Moderate

This is a pooled review of 29,625 participants. Across 113 studies, blood p-tau217 identified Alzheimer's pathology about 88% of the time and outperformed other tau variants like p-tau181. Its stated limit: About 90% of the pooled studies were rated high risk of bias due to lack of predefined thresholds, per the authors' own assessment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Therriault, J., Zetterberg, H., Blennow, K., Rosa-Neto, P., et al. (2025). Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(25)00227-3

Vancouver

Therriault J, Zetterberg H, Blennow K, Rosa-Neto P, et al. Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. The Lancet Neurology. 2025. doi:10.1016/s1474-4422(25)00227-3. PMID: 40818474.

BibTeX

@article{therriault2025-1f9fdc81,
  author  = {Therriault, Joseph and Zetterberg, Henrik and Blennow, Kaj and Rosa-Neto, Pedro and others},
  title   = {{Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis}},
  journal = {The Lancet Neurology},
  year    = {2025},
  doi     = {10.1016/s1474-4422(25)00227-3},
  pmid    = {40818474},
  url     = {https://doi.org/10.1016/s1474-4422(25)00227-3}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Across 113 studies, blood p-tau217 identified Alzheimer's pathology about 88% of the time and outperformed other tau variants like p-tau181. The authors warn that about 90% of the pooled studies had a high risk of bias from lack of predefined thresholds, so the reported accuracy may be inflated.

Study details

Limitations

About 90% of the pooled studies were rated high risk of bias due to lack of predefined thresholds, per the authors' own assessment.

How this study scored 76/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 12 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 0 of 2; Free to read left out, no data. 47 of the 62 points it could be judged on, which is 76 of 100. Total 76 of 100.47 of the 62 points we could judge = 76 of 100

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 47 of the 62 points we could judge it on, which is 76 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet Neurology)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 29,625 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 0 / 2 No PubMed ID and no DOI — scores zero (not stated in the record — scored 0)
Free to read — / 2 Access not recorded — left out of this score
Points 47 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 47 of the 62 points we could judge it on is 76 out of 100.
Total 76 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “phosphorylated”

733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →